Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)
Year: 2018
Type: article
Source: Annals of Oncology
Authors: R.S. Herbst, E.B. Garon, D.-W. Kim, B. Chul Cho, J.L. Pérez Gracia, J.-Y. Han, C. Dubos Arvis, M. Majem, M. Forster, I. Monnet, S. Novello, Z. Szalai, M.A. Gubens, W.-C. Su, G.L. Ceresoli, A. Samkari, E. Jensen, G.M. Lubiniecki, P. Baas
Institutions: Yale University, University of California, Los Angeles, Seoul National University Hospital, Yonsei University, Yonsei Cancer Hospital, Clinica Universidad de Navarra, National Cancer Center, Centre François Baclesse, Hospital de Sant Pau, University College Hospital, University College London, Hôpital Intercommunal de Créteil, Ospedale San Luigi Gonzaga, University of Turin, Petz Aladár Megyei Oktató Kórház, University of California, San Francisco, National Cheng Kung University Hospital, Humanitas Gavazzeni, Merck & Co., Inc., Rahway, NJ, USA (United States), Amsterdam UMC Location University of Amsterdam, The Netherlands Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Merck, Merck Sharp and Dohme
OpenAlex ID: W2898524274